Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Katharine J. Bee
Observed names:
Bee, Katharine J,
Bee, Katharine J.,
K. Bee,
KATHARINE J. BEE,
Katharine Bee,
Katharine J Bee
show all 6
Institution:
DBV Technologies (France)
Observed institutions:
Albert Einstein College of Medicine,
DBV Technologies (France),
Cornell University,
DBV Technology (United States),
Weill Cornell Medicine
OpenAlex ID:
A5070049516
Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy
2023
·
Matthew Greenhawt
, Sayantani B. Sindher
, et al.
·
New England Journal of Medicine
·
157
PDF
A KCNE2 mutation in a patient with cardiac arrhythmia induced by auditory stimuli and serum electrolyte imbalance
2007
·
Earl Gordon
, Gianina Panaghie
, et al.
·
Cardiovascular Research
·
49
PDF
Zebrafish brd2a and brd2bare paralogous members of the bromodomain-ET (BET) family of transcriptional coregulators that show structural and expression divergence
2008
·
Angela J DiBenedetto
, Jake B Guinto
, et al.
·
BMC Developmental Biology
·
25
PDF
Recent advances in epicutaneous immunotherapy and potential applications in food allergy
2023
·
Pierre-Louis Hervé
, Vincent Dioszeghy
, et al.
·
Frontiers in Allergy
·
24
PDF
Genetic and Epigenetic Variations of HPV52 in Cervical Precancer
2021
·
Katharine J. Bee
, Ana Gradissimo
, et al.
·
International Journal of Molecular Sciences
·
24
PDF
TGFβRIIb Mutations Trigger Aortic Aneurysm Pathogenesis by Altering Transforming Growth Factor β2 Signal Transduction
2012
·
Katharine J. Bee
, David C. Wilkes
, et al.
·
Circulation Cardiovascular Genetics
·
22
Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers: Open-Label Extension to EPITOPE
2025
·
Matthew Greenhawt
, Deborah Albright
, et al.
·
The Journal of Allergy and Clinical Immunology In Practice
·
20
Varying Doses of Epicutaneous Immunotherapy With Viaskin Milk vs Placebo in Children With Cow’s Milk Allergy: A Randomized Clinical Trial
2024
·
Daniel Petroni
, Philippe Bégin
, et al.
·
Archives of Pediatrics and Adolescent Medicine
·
20
PDF
Epicutaneous immunotherapy for the treatment of peanut allergy
2024
·
Mayuran Ravindran
, Hugh A. Sampson
, et al.
·
Allergy
·
17
PDF
Structural and Functional Genetic Disorders of the Great Vessels and Outflow Tracts
2006
·
KATHARINE J. BEE
, DAVID WILKES
, et al.
·
Annals of the New York Academy of Sciences
·
15
PDF
Evaluation of daily patch application duration for epicutaneous immunotherapy for peanut allergy
2020
·
David M. Fleischer
, Jonathan M. Spergel
, et al.
·
Allergy and Asthma Proceedings
·
10
Safety and efficacy of epicutaneous immunotherapy with DBV712 (peanut patch) in peanut allergy
2024
·
Christophe Dupont
, A. Wesley Burks
, et al.
·
Expert Review of Clinical Immunology
·
9
PDF
Efficacy and safety of peanut epicutaneous immunotherapy in patients with atopic comorbidities
2022
·
Carla M. Davis
, Lars Lange
, et al.
·
Journal of Allergy and Clinical Immunology Global
·
9
PDF
An evaluation of factors influencing response to epicutaneous immunotherapy for peanut allergy in the PEPITES trial
2020
·
David M. Fleischer
, Sharon Chinthrajah
, et al.
·
Allergy and Asthma Proceedings
·
9
Long-Term Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: An Open-Label Active Treatment (REALISE Study)
2025
·
Jacqueline A. Pongracic
, Rémi Gagnon
, et al.
·
The Journal of Allergy and Clinical Immunology In Practice
·
8
PDF
Reduction in peanut reaction severity during oral challenge after 12 months of epicutaneous immunotherapy
2021
·
Philippe Bégin
, John Andrew Bird
, et al.
·
Allergy
·
6
Efficacy and safety of epicutaneous immunotherapy in children with peanut allergy with atopic comorbidities
2025
·
Amy M. Scurlock
, David M. Fleischer
, et al.
·
Annals of Allergy Asthma & Immunology
·
4
Efficacy and Safety of Epicutaneous Immunotherapy (EPIT) for Peanut Allergy in Subjects Aged 1-3 Years With and Without Atopic Dermatitis in the EPITOPE Study
2023
·
Amy Scurlock
, Katharine Bee
, et al.
·
Journal of Allergy and Clinical Immunology
·
3
Epopex, Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-allergic Toddlers: 1-year Open-label Extension to Epitope
2023
·
M. Greenhawt
, J. Wang
, et al.
·
Annals of Allergy Asthma & Immunology
·
1
VITESSE Phase 3 Study: Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children 4 Through 7 Years of Age
2026
·
David Fleischer
, Douglas Mack
, et al.
·
Journal of Allergy and Clinical Immunology
PDF
Long-term Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-allergic Toddlers: Epopex End of Study Results
2025
·
M. Greenhawt
, J. Wang
, et al.
·
Annals of Allergy Asthma & Immunology
Pooled Safety Data from Phase 3 Studies of Epicutaneous Immunotherapy for Peanut Allergy in Children Aged 4-11 Years
2022
·
Jacqueline Pongracic
, Andrew Bird
, et al.
·
Journal of Allergy and Clinical Immunology
P300 Evaluation of Daily Patch Application Duration for Epicutaneous Immunotherapy for Peanut Allergy
2020
·
J. Spergel
, D. Fleischer
, et al.
·
Annals of Allergy Asthma & Immunology
P301 Evaluation of Factors Influencing Response to Epicutaneous Immunotherapy for Peanut Allergy in the Pepites
2020
·
A. Scurlock
, D. Fleischer
, et al.
·
Annals of Allergy Asthma & Immunology
Show more works
View as search
Works count:
37
Citation count:
432
H-index:
10
I10-index:
11
Year
Topic
Type